

Rachel King is BIO chairperson for 2013-14

23 April 2013 | Influencers | By BioSpectrum Bureau



Singapore: Biotechnology Industry Organization (BIO) has elected Ms Rachel King, president and CEO, GlycoMimetics, as the new chair of its board of directors for the 2013-14 term and Mr David Pyott, chairman, president, and CEO, Allergan, as its new board secretary.

BIO re-elected Mr Mark Skaletsky, chairman and CEO, Fenway Pharmaceuticals, as board treasurer, and the election of 19 directors to serve on BIO's board executive committee for the new term, including Mr Ron Cohen, president & CEO, Acorda Therapeutics as health section vice chair; Mr Adam Monroe, president, Novozymes North America, Novozymes, as industrial and environmental section (IES) governing board chair; and Mr Rick Eno, president and CEO, Metabolix, as IES governing board vice chair, among others.